FcRn inhibitors for myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Current treatments aim to manage symptoms and immune responses.
• FcRn inhibitors represent a novel therapeutic approach for MG.

Purpose of the Study:

• To evaluate the benefits and harms of FcRn inhibitors for maintenance treatment in adult myasthenia gravis patients.
• To compare FcRn inhibitors against control treatments, including placebo, standard care, or other immunomodulatory therapies.
• To explore differential effects across participant subgroups and treatment regimens.

Main Methods:

• Systematic review of randomized controlled trials and observational studies.
• Assessment of efficacy using validated MG measurement tools for disease severity and functional impairment.
• Analysis of safety data regarding adverse events associated with FcRn inhibitors.

Main Results:

• The review will synthesize evidence on the efficacy of FcRn inhibitors in reducing MG symptoms and improving function.
• Harms and safety profiles of FcRn inhibitors will be systematically documented.
• Subgroup analyses will identify patient populations and treatment strategies yielding the greatest benefit.

Conclusions:

• FcRn inhibitors show potential as a maintenance therapy for myasthenia gravis.
• Evidence synthesis will guide clinical decision-making and policy development.
• This review will clarify the role of FcRn inhibitors in optimizing MG management.